Abstract
With just one drug used for individual patient management and community-based morbidity control, the treatment, control, and eventual elimination of schistosomiasis is vulnerable should resistance to praziquantel emerge and spread. The discovery and development of novel chemical entities that exhibit antischistosomal properties, and the repurposing of existing drugs for schistosomiasis is thus of central importance as long as praziquantel remains effective. Here, we discuss the public health relevance of schistosomiasis, which is currently considered a neglected tropical disease. We recapitulate the past and current drug armamentarium against schistosomiasis, including shortcomings and a target product profile of an antischistosomal drug. The central piece of our review is the discovery of the antischistosomal properties of various antimalarial drugs, notably the artemisinins, synthetic trioxolanes, and mefloquine. We summarize findings from preclinical investigations and experiences made thus far from clinical studies. We conclude that a closer collaboration between the malaria and schistosomiasis communities might facilitate the discovery and development of novel antischistosomal drugs, and will foster monitoring and evaluation of the ancillary benefits of antimalarial prophylaxis and treatment against schistosomiasis.
Keywords: Schistosomiasis, malaria, antimalarial drugs, artemisinins, synthetic trioxolanes, mefloquine, morbidity control, praziquantel, antischistosomal drug, prophylaxis
Current Pharmaceutical Design
Title:Antimalarials in the Treatment of Schistosomiasis
Volume: 18 Issue: 24
Author(s): Jennifer Keiser and Jurg Utzinger
Affiliation:
Keywords: Schistosomiasis, malaria, antimalarial drugs, artemisinins, synthetic trioxolanes, mefloquine, morbidity control, praziquantel, antischistosomal drug, prophylaxis
Abstract: With just one drug used for individual patient management and community-based morbidity control, the treatment, control, and eventual elimination of schistosomiasis is vulnerable should resistance to praziquantel emerge and spread. The discovery and development of novel chemical entities that exhibit antischistosomal properties, and the repurposing of existing drugs for schistosomiasis is thus of central importance as long as praziquantel remains effective. Here, we discuss the public health relevance of schistosomiasis, which is currently considered a neglected tropical disease. We recapitulate the past and current drug armamentarium against schistosomiasis, including shortcomings and a target product profile of an antischistosomal drug. The central piece of our review is the discovery of the antischistosomal properties of various antimalarial drugs, notably the artemisinins, synthetic trioxolanes, and mefloquine. We summarize findings from preclinical investigations and experiences made thus far from clinical studies. We conclude that a closer collaboration between the malaria and schistosomiasis communities might facilitate the discovery and development of novel antischistosomal drugs, and will foster monitoring and evaluation of the ancillary benefits of antimalarial prophylaxis and treatment against schistosomiasis.
Export Options
About this article
Cite this article as:
Keiser Jennifer and Utzinger Jurg, Antimalarials in the Treatment of Schistosomiasis, Current Pharmaceutical Design 2012; 18 (24) . https://dx.doi.org/10.2174/138161212801327293
DOI https://dx.doi.org/10.2174/138161212801327293 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Formulation and Evaluation of Isoniazid Loaded Nanosponges for Topical Delivery
Pharmaceutical Nanotechnology Nicotinic Acid Benzylidene/Phenyl-Ethylidene Hydrazides: Synthesis, Antimicrobial Evaluation and QSAR Studies
Letters in Drug Design & Discovery Synthesis and Evaluation of Bis-pyrazoline Derivatives as Potential Antimicrobial Agents
Letters in Drug Design & Discovery Inside the Pan-genome - Methods and Software Overview
Current Genomics Molecular Docking Evaluation of Imidazole Analogues as Potent Candida albicans 14α-Demethylase Inhibitors
Current Computer-Aided Drug Design Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis
Current Pharmaceutical Biotechnology Anti-Inflammatory Therapy in Uveitis
Recent Patents on Inflammation & Allergy Drug Discovery Anti Tumor Necrosis Factor Alpha (TNFα) Therapy in Ankylosing Spondylitis - Asian Perspective
Current Rheumatology Reviews Concepts for Nano-delivery of Therapeutic Immunomodulatory Agents
Current Bionanotechnology (Discontinued) Wzy-Dependent Bacterial Capsules as Potential Drug Targets
Current Drug Targets Potential Drugs for the Treatment of COVID-19: Synthesis, Brief History and Application
Current Drug Research Reviews Heat Shock Protein 90 Inhibitors as Broad Spectrum Anti-Infectives
Current Pharmaceutical Design Understanding the Pharmaceutical Aspects of Dendrimers for the Delivery of Anticancer Drugs
Current Drug Targets Nanoparticle-Based Diagnosis and Therapy
Current Drug Targets Invasive Pulmonary Aspergillosis in Acute Leukemia: Current Issues for Pathogenesis, Diagnosis and Treatment
Current Respiratory Medicine Reviews Toll Like Receptor - Potential Drug Targets in Infectious Disease
Infectious Disorders - Drug Targets An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry Synthesis of Novel Quinolone and Coumarin Based 1,3,4-Thiadiazolyl and 1,3,4-Oxadiazolyl N-Mannich Bases as Potential Antimicrobials
Letters in Organic Chemistry The Role of Mineral Deficiencies in Insulin Resistance and Obesity
Current Diabetes Reviews Formulation and Evaluation of Rifampicin Liposomes for Buccal Drug Delivery
Current Drug Delivery